EydisBio is a small biotech located in Durham, NC which originated in 2016 as a spin out of Dr. Timothy Haystead’s lab at Duke University (Duke). To date, the Company has secured approximately $3.3 million in non-dilutive funding through various Phase I and II NIH SBIR/STTR grants, as well as small grants from the North Carolina Biotechnology Center, North Carolina SBIR/STTR Phase I Matching Funds Program, and convertible debt from Duke’s MedBlue Incubator. While our near-term focus has been to secure non-dilutive funding to build value and de-risk our programs, we will continue to engage with investors and potential pharmaceutical partners to provide the necessary capital and resources needed to successfully expand our R&D and operations into and through clinical trials, and towards commercialization. With a focus on autoimmune and inflammatory diseases, EydisBio’s current goal is to advance our lead TAK1 inhibitor, EYD-001, through IND and towards clinical trials. To date we have developed an orally bioavailable TAK1 inhibitor which shows very promising in vitro and in vivo data in treating SSc, RA, neuropathic pain, and COVID-19 induced ARDS. At present, we are advancing EYD-001 through pre-IND enabling safety studies en route to IND-enabling safety studies (i.e., GLP tox) in preparation for IND filing. However, we are also exploring EYD-001’s potential in other indications as well, such as, systemic lupus erythematous, psoriasis, and others.